Floatz logo

Cladribine

Small Intestine Cancer

Northwestern UniversitySmall moleculePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

21 Active assets in the Small Intestine Cancer cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2BB
ETOPOSIDE
Cancer Research UK
Phase 2BB
VINCRISTINE SULFATE
Cancer Research UK
Phase 2BB
FILGRASTIM
Cancer Research UK
Phase 2BB
Inno-206
Cancer Research UK
Phase 2B

View all 50 →

Same molecule, other indications

Cladribine is also rated in:

relapsing-remitting multiple sclerosisDormant
BBB
Indicative ·
76 / 100
View asset →
lymphoblastic lymphomaDormant
BBB
Indicative ·
75 / 100
View asset →
multiple sclerosisDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →